Heart attack

February 20, 2019

Ribonucleic acid-based therapy for myocardial diseases: LncRNA FEZF1-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.48 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
February 20, 2019

Ribonucleic acid-based therapy for myocardial diseases: LncRNA TNK-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.29 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
February 20, 2019

Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: Teneligliptin (Brand name: Tenilia), an anti-hyperglycemic medication used in the treatment of TIIDM, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 21/February/2019, 12.09 am

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]
February 15, 2019

Empagliflozin (EMBA)-based therapy for Cardiac repair and myocardial infarction: Empagliflozin (EMBA) (trade name: Jardiance), a sodium-glucose cotransporter 2 inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019,  7.37 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]